Critique Pembrolizumab (Keytruda): CADTH Reimbursement Advice: Indication: In combination with chemotherapy, for that therapy of adult sufferers with domestically recurrent unresectable or metastatic triple-unfavorable breast most cancers who've not obtained prior chemotherapy for metastatic sickness and whose tumours express programmed cell Loss o